PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

sarilumab

Verify with FDA → · CMS NADAC pricing →

Brand names: Kevzara

IL-6 Receptor Antagonist Rx

Kevzara is a medicine that can help treat rheumatoid arthritis, polymyalgia rheumatica and polyarticular juvenile idiopathic arthritis. It works by blocking a protein in your body that causes inflammation.

Drug Pricing (NADAC)

Brand Price

$1852.54/unit

Generic Available

No

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

What it does

Kevzara treats rheumatoid arthritis (RA) in adults when other medicines have not worked well enough.

Common side effects

Low white blood cell count (neutropenia), Increased liver enzyme levels, Redness at the injection site

Key warnings

Kevzara can increase your risk of serious infections that could lead to hospitalization or death.

How It Works

Kevzara is an interleukin-6 (IL-6) receptor antagonist. This means it blocks the IL-6 receptor. By blocking this receptor, Kevzara reduces inflammation in your body.

How to Take It

Kevzara is given as an injection under your skin (subcutaneously). For RA and PMR, the usual dose is 200 mg once every 2 weeks. For pJIA patients who weigh 63 kg or greater, the recommended dose is 200 mg once every 2 weeks. Your doctor may adjust your dose based on lab results.

Pregnancy & Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Kevzara will harm your unborn baby. Talk to your doctor about the risks and benefits of taking Kevzara during pregnancy and breastfeeding.

Missed Dose

If you miss a dose of Kevzara, inject it as soon as you remember. Then, continue with your regular schedule.

Storage

Keep Kevzara in the refrigerator at 36°F to 46°F (2°C to 8°C) in its original carton to protect it from light. Do not freeze or shake it. If needed, you can store Kevzara at room temperature up to 77°F (25°C) for up to 14 days.

Side Effects (from patient reports)

Based on 40,317 FDA adverse event reports.

The medicine is not working
5,591
Pain
5,313
Joint pain
4,655
Rheumatoid arthritis
4,395
Swollen joint
4,362
Condition is getting worse
3,580
Tiredness
3,334
Skin rash
3,212
Hair loss
2,969
Stomach discomfort
2,906

FDA Adverse Event Report Analysis

Detailed analysis of 23,683 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2015–2025.

Total Reports

23,683

Death-Related Reports

2,313

Hospitalization Reports

4,047

Top Indication

Rheumatoid Arthritis

Gender Distribution

Female 17,963 (84%)
Male 3,459 (16%)

Age Distribution

0–17 53
18–44 3,620
45–64 7,520
65–74 2,758
75+ 1,631

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 DRUG INEFFECTIVE 5,591
2 PAIN 5,313
3 ARTHRALGIA 4,655
4 RHEUMATOID ARTHRITIS 4,395
5 JOINT SWELLING 4,362
6 CONDITION AGGRAVATED 3,580
7 FATIGUE 3,334
8 RASH 3,212
9 ALOPECIA 2,969
10 ABDOMINAL DISCOMFORT 2,906
11 HEPATIC ENZYME INCREASED 2,858
12 SYSTEMIC LUPUS ERYTHEMATOSUS 2,780
13 PEMPHIGUS 2,721
14 HAND DEFORMITY 2,643
15 GLOSSODYNIA 2,625

Reactions in Death Reports

SYSTEMIC LUPUS ERYTHEMATOSUS 1,016
DUODENAL ULCER PERFORATION 1,014
ABDOMINAL DISCOMFORT 994
PEMPHIGUS 978
TYPE 2 DIABETES MELLITUS 975
PERICARDITIS 971
RHEUMATOID ARTHRITIS 966
ALOPECIA 950
HAND DEFORMITY 943
BLOOD CHOLESTEROL INCREASED 938

Reactions in Hospitalization Reports

RHEUMATOID ARTHRITIS 1,464
ABDOMINAL DISCOMFORT 1,402
ALOPECIA 1,321
SYSTEMIC LUPUS ERYTHEMATOSUS 1,319
ARTHRALGIA 1,297
HEPATIC ENZYME INCREASED 1,293
DUODENAL ULCER PERFORATION 1,288
FATIGUE 1,263
PERICARDITIS 1,263
HELICOBACTER INFECTION 1,256

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Kevzara can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have an active infection before starting Kevzara. Your doctor should test you for tuberculosis (TB) before you start Kevzara. If you get a serious infection, your doctor will stop Kevzara treatment until the infection is controlled.

Known Drug Interactions

Exercise caution when co-administering KEVZARA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

Mechanism: Sarilumab can make your body process atorvastatin more quickly than usual. This can make the atorvastatin less effective at lowering your cholesterol.

What to do: Your doctor should monitor your cholesterol levels closely. They may need to adjust your atorvastatin dose to ensure it is still working.

moderate lovastatin

Exercise caution when co-administering KEVZARA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

Mechanism: Sarilumab speeds up the way your body gets rid of lovastatin. This reduces the amount of medicine in your system, making it less effective.

What to do: Use caution when taking these drugs together and have your cholesterol checked regularly. Your doctor might need to increase your lovastatin dose.

Upon initiation or discontinuation of KEVZARA, in patients being treated with CYP substrate medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., theophylline) and adjust the individual dose of the medicinal product as needed.

Mechanism: Sarilumab can change how quickly your body breaks down warfarin, which can affect how much your blood is thinned. This could lead to your blood being too thick or too thin.

What to do: Your doctor should monitor your blood clotting levels closely and may need to adjust your warfarin dose when you start or stop this treatment.

7 DRUG INTERACTIONS 7.1 Use with Other Drugs Population pharmacokinetic analyses did not detect any effect of methotrexate (MTX) on sarilumab clearance.

Mechanism: Methotrexate does not affect how the body processes or removes sarilumab.

What to do: No dose adjustments are needed when these two medications are used together.

Upon initiation or discontinuation of KEVZARA, in patients being treated with CYP substrate medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., theophylline) and adjust the individual dose of the medicinal product as needed.

Mechanism: Sarilumab can change how the liver breaks down theophylline, which might change the amount of medicine in your blood.

What to do: Your doctor should monitor your theophylline levels and adjust your dose if necessary when starting or stopping sarilumab.

Common Questions

What should I tell my doctor before taking Kevzara?
Tell your doctor if you have any infections, liver problems, or have had TB.
Can I take Kevzara with other medicines?
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will my doctor monitor me while I'm taking Kevzara?
Your doctor will do blood tests to check your white blood cell count, liver function, and cholesterol levels.
Can I get vaccines while taking Kevzara?
Avoid live vaccines while taking Kevzara.
What are the signs of a serious infection?
Signs include fever, cough, shortness of breath, weight loss, night sweats, diarrhea, or stomach pain.
What should I do if I have side effects?
Tell your doctor about any side effects you experience while taking Kevzara.
Can Kevzara affect my cholesterol?
Yes, Kevzara can increase your cholesterol levels.
Is it safe to take Kevzara if I have diabetes?
Talk to your doctor about the risks and benefits of taking Kevzara if you have diabetes.
How is Kevzara supplied?
Kevzara comes in pre-filled syringes and pre-filled pens.
What if I accidentally leave Kevzara out of the refrigerator?
If needed, you can store Kevzara at room temperature up to 77°F (25°C) for up to 14 days.
What are the common side effects of sarilumab?
The most commonly reported side effects of sarilumab include Low white blood cell count (neutropenia), Increased liver enzyme levels, Redness at the injection site, Upper respiratory infections, Urinary tract infections. Based on 40,317 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does sarilumab interact with other medications?
Yes, sarilumab has 5 known drug interactions. Notable interactions include atorvastatin, lovastatin, warfarin. Always inform your doctor about all medications you are taking.
What drug class is sarilumab?
sarilumab belongs to the IL-6 Receptor Antagonist drug class. It requires a prescription (Rx). Kevzara treats rheumatoid arthritis (RA) in adults when other medicines have not worked well enough.
Is sarilumab safe during pregnancy?
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Kevzara will harm your unborn baby. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in IL-6 Receptor Antagonist

Other drugs grouped near sarilumab — same-class peers and common alternatives.

Compare sarilumab vs abatacept side-by-side →

Medication Guides

Related Health & Safety Data

Save on sarilumab

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for sarilumab

The FDA label for sarilumab (sold under brand names such as Kevzara) classifies it as a prescription-only medication in the IL-6 Receptor Antagonist class. Kevzara treats rheumatoid arthritis (RA) in adults when other medicines have not worked well enough. Official labeling lists 8 commonly reported side effects, including Low white blood cell count (neutropenia), Increased liver enzyme levels, Redness at the injection site.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 40,317 voluntary reports. The database also lists 5 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: May 16, 2025

All federal data sources used on this page